UPCC 13118: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant Palbociclib and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  breast cancer
• Age: - 99 Years
• Gender: All